Pharmacokinetic Comparison of SCT800 (B-domain Deleted Recombinant Factor VIII) With Xyntha in Previously Treated Patients With Hemophilia A: a Phase I, Open-label, Randomized, Crossover Study

Trial Profile

Pharmacokinetic Comparison of SCT800 (B-domain Deleted Recombinant Factor VIII) With Xyntha in Previously Treated Patients With Hemophilia A: a Phase I, Open-label, Randomized, Crossover Study

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Moroctocog alfa (Primary) ; SCT 800 (Primary)
  • Indications Haemophilia A
  • Focus Pharmacokinetics
  • Sponsors Sinocelltech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top